Compare BRNX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRNX | ONCO |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.0M |
| IPO Year | 2022 | 2021 |
| Metric | BRNX | ONCO |
|---|---|---|
| Price | $1.06 | $0.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 107.7K | ★ 6.4M |
| Earning Date | 09-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $815,371.00 |
| Revenue This Year | $35,081.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $0.09 |
| 52 Week High | $10.36 | $798.00 |
| Indicator | BRNX | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 31.29 | 37.94 |
| Support Level | N/A | $0.09 |
| Resistance Level | $2.49 | $1.02 |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 15.09 | 1.39 |
BrenX Ltd is reshaping industrial energy to make it cleaner, more reliable, and lower cost. Building on its proprietary bGen thermal energy storage technology, which converts electricity and recovered heat into dispatchable energy, BrenX develops, owns, operates, and optimizes energy assets that serve industrial customers and data centers. From local generation and storage to grid connectivity and intelligent energy management, BrenX brings together technologies and infrastructure to create complete energy platforms around customer needs, with flexible energy assets designed to meet growing energy demand.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.